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ABSTRACT
Introduction: Celiac disease (CD) is an immune-mediated disorder associated with gluten exposure in
genetically predisposed subjects.
Areas covered: Infectious disease is one of the causes of morbidity and mortality in CD patients.
Invasive streptococcus pneumoniae (pneumococcus) is a particularly dangerous morbid condition in
both the general population and celiac patients. Pneumococcal vaccination is the most effective means
for its prevention.
Expert opinion: In CD, evaluation of spleen function should be useful to select patients who may
benefit from vaccination to reduce the risk of pneumococcal disease. Different strategies could be
employed: physicians could search for signs of hyposplenism on peripheral blood smear or abdominal
ultrasound. However, the best strategy to identify which patients will benefit from pneumococcal
vaccination has not yet been defined.
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1. Introduction
Celiac disease (CD) is a chronic immune-mediated gastrointest-
inal disorder found in more than 1% of the Western population
and caused by gluten exposure in genetically predisposed sub-
jects. It is strongly associated with HLA DQ-2 and DQ-8 haplo-
types, and exposure to diets containing gluten can lead to the
development of the disease with its typical and atypical symp-
toms, associated with the development of circulating autoanti-
bodies (anti-transglutaminase and anti-endomysial antibodies),
and duodenal histology alterations, ranging frommild (increased
intraepithelial lymphocytes) to severe (villous atrophy). A gluten-
free diet is the only efficacious treatment for CD [1,2].
In addition to its several clinical manifestations, CD is also
associated with a predisposition for infectious disease, which can
increasemorbidity andmortality. Several studies have reported an
increased risk of urinary tract infections [3], tuberculosis infection
[4], invasive pneumococcus infection [5,6], and sepsis [7].
Many factors can influence immune response in CD
patients. A decrease in splenic function due to
hyposplenism or atrophy is often detected in CD, possibly
resulting in a reduced response to bacterial infections [8].
The present paper aims to review the causes of the
increased risk of infection in CD and the evidence regarding
pneumococcal infection and vaccination in CD.
2. Hyposplenism and infections in CD
The importance of the spleen in maintaining the immunoglobulin
(Ig)M memory B-cell pool has been demonstrated, as well as its
fundamental role in protecting against infection by encapsulated
bacteria. Memory B cells, produced in response to infectious
agents or vaccines, persist in the organism and rapidly produce
antibodies following a second stimulation with the same patho-
gen. In humans, about half of B cells express CD27 and are
considered memory B cells. IgM memory B cells have different
origins and functions from switched memory B cells. They are not
present in splenectomized and asplenic patients, whereas
switched memory B cells are only transiently depleted after sple-
nectomy and are normally detectable in asplenic patients. IgM
memory B cells originate from the spleen marginal zone, which
supports IgM memory B cell survival. These cells produce natural
antibodies (mostly of IgM type) necessary for T-independent
response to encapsulated bacteria. By opsonizing invading patho-
gens, natural antibodies also play a crucial role in activating the
complement cascade and amplifying early innate defense
mechanisms [9]. More specifically, an impairment of the immune
function of the spleen results in: (a) a reduction in IgM-memory
B cells and a defective opsonization activity, thus predisposing to
infections caused by encapsulated bacteria (mainly Streptococcus
pneumoniae, Neisseria meningitidis and Haemophylus influenzae);
and (b) a decrease in marginal zone B cells which, in turn, predis-
poses to the emergence of autoreactive T-cell clones, as
a consequence of contemporary T-regulatory cell depletion, with
the subsequent development of autoimmunity. Moreover, it must
be remembered that the spleen also has an important filtering
function; impairment results in (a) the defective removal of pits
from erythrocytes, with a consequent increase in circulating pitted
red cells and Howell-Jolly bodies, and (b) reduced platelet
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sequestration, leading to thrombocytosis, which, in turn, predis-
poses to thromboembolism [10,11].
Consequently, in splenectomized and asplenic patients,
a contemporaraneous impairment of both the immune and
filtering function has been shown, and a significant inverse
correlation between levels of circulating IgM memory B cells
(detected by flow-cytometry) and pitted red cell values has
been reported in inflammatory bowel disease patients with
hyposplenism [12].
Therefore, in accordance with Di Sabatino et al. [11], we can
suggest that CD patients should be considered as suffering
from major hyposplenism when an IgM memory B cell fre-
quency lower than 10 and/or a pitted red cell value higher
than 4% are present, indicating that this population could
receive more clinical benefits from pneumococcal vaccination.
Pitted red cell count can be considered as the reference
method for diagnosing hyposplenism. Although this approach
could be considered simple, ‘pit identification’ (a pit being the
characteristic depression on the erythrocyte surface) in a blood
smear requires the use of special equipment (Zeiss/Nomarski
differential interference contrast microscopy) which is not so
readily available.
In addition to the presence of low IgM memory B cells,
increased pitted red blood cells, and Howell-Joly bodies, sim-
ple evaluation of spleen size and volume by abdominal ultra-
sound can be considered the first step in detecting
hyposplenism. In this context, Di Sabatino et al. showed that
two-thirds of individuals with a small spleen (longitudinal
diameter <7.5–8 cm, incidentally detected on abdominal ultra-
sound) had splenic hypofunction, with pitted erythrocyte
levels comparable to those of splenectomized patients [13].
CD is the most frequent of the various diseases associated
with hyposplenism, which affects more than a third of celiac
patients. It does not complicate CD in infancy, whereas in
adults its incidence correlates with the duration of previous
exposure to gluten, and a gluten-free diet is effective in restor-
ing splenic function. The prevalence of hyposplenism
increases from 19% to 80% in celiac patients with autoim-
mune disorders (AID) and/or premalignant or malignant com-
plications. Therefore, splenic atrophy is recognized as a factor
associated with a worse prognosis in CD [14,15].
In this context, Di Sabatino et al. demonstrated that in
patients with complicated CD and in celiac patients with AID
the median percentage of pitted red cells (9.3% and 4.9%,
respectively) was significantly higher than in uncomplicated
celiac patients without AID (median 2.6%; P < .005), and in non-
celiac patients with AID (median pitted red cells 1.8%; P < .001)
and healthy volunteers (median pitted red cells 0.9%; P < .0001).
As expected, splenectomized patients had a significantly higher
number of pitted red cells (median 15.8%, range 8.4–2.5; P < .005)
than patients with complicated CD. The prevalence of splenic
hypofunction (pitted red cells >4%) was significantly higher in
patients with complicated and AID-associated CD than in
patients with uncomplicated CD without AID [15].
As quoted above, hyposplenism in CD can cause severe
infections, mainly due to encapsulated bacteria, such as
Pneumococcus. This kind of infection triggers the response of
natural IgM antibodies, produced by memory B-cell popula-
tions residing in the marginal zone of the spleen, which in turn
are responsible for the activation of T-independent immune
responses against encapsulated bacteria [11].
In CD patients, malnutrition and increased intestinal perme-
ability may be other factors predisposing to an impairment of
the immune system’s ability to respond to infections [16].
Reduced serum levels of folate, vitamin B12 and vitamin
D are frequent in CD patients and may contribute to the
reduction in immunologic functions [17].
Increased intestinal permeability has been recognized as
one of the events predisposing to the development of multi-
ple organ failure in critically ill ICU patients [18], although this
aspect has not yet been confirmed in CD patients. It is impor-
tant to underline that, in addition to increased intestinal per-
meability, CD patients also show an increased permeability of
the respiratory mucosa [19].
Streptococcus pneumoniae is a particularly significant
infection in CD patients; as a consequence, the British
Society of Gastroenterology has recommended the vaccina-
tion of all CD patients against pneumococcal disease (grade
C recommendation) [20].
The British Guidelines based this recommendation on the
evidence that CD is often associated with hypoplasia and that
splenic atrophy is a known risk factor for encapsulated bacter-
ial infections, such as Pneumococcus [21].
However, neither the American College of Gastroenterology
nor other Gastroenterology societies have specifically recom-
mended vaccination for celiac patients [22], whereas it is recom-
mended, in general, for patients with splenic atrophy or
asplenia [22].
3. International literature data about the dimension
of the problem
Early evidence on the risk of streptococcus pneumoniae
(Pneumococcus) infection and fatal septicemia in CD patients
was provided only by case reports, which documented a lack
of response to standard therapy and the absence of other risk
factors than CD and hyposplenism [23–25].
It is currently being debated how frequently pneumococcal
infections occur in CD populations compared to the general
population. Several studies have investigated this aspect, both
before and after the current British Guidelines were introduced.
Article highlights
● Impairment of the immune function of the spleen results in
a reduced number of IgM-memory B cells, the emergence of auto-
reactive T-cell clones, defective removal of pits from erythrocytes, and
reduced platelet sequestration, with thrombocytosis
● Hyposplenism, a well-known risk factor for pneumococcal infection, is
not routinely investigated and evaluated in celiac patients
● Every physician should investigate blood and/or ultrasound signs of
hyposplenism and splenic atrophy in CD patients
● A systematic evaluation of spleen function should permit the selec-
tion of CD patients who may benefit from vaccination, in order to
reduce the risk of invasive pneumococcal disease
● Celiac patients with impaired immunologic function need to undergo
a complete vaccination protocol, including S. pneumoniae,
N. meningitidis, H. influenzae type B, and influenza.
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Thomas et al. [5] reported that CD patients have a higher risk of
invasive pneumococcal disease than the general population,
with a rate ratio of 2.06 (95% confidence interval, CI
1.27–3.15) in an Oxford population and a rate ratio of 1.61
(95% CI 1.36–1.90) in England as a whole. A higher risk of
pneumococcal infection in splenectomized patients was
reported, with a rate ratio of 3.40 (95% CI 2.44–4.60) in an
Oxford population and 3.32 (95% CI 2.80–3.90) in England as
a whole. The authors stressed that CD patients aged between
15 and 64 and over 65 had a higher risk than controls, whereas
in patients under 15 years of age there was no significant
difference in risk of pneumococcal infections.
Rochert Tjemberg et al. [6], in a population-based cohort
study on invasive pneumococcal disease in Sweden, showed an
increased risk in CD patients about 46% higher than in the
general population. The study included 29,012 individuals with
biopsy-proven CD, matchedwith 144,257 controls, and the infec-
tion events of Pneumococcus were identified through regional
and national microbiological databases. Recorded pneumococ-
cal infection was 45/29,012 in the CD patients (0.15%) and 162/
144,257 in controls (0.11%) (Hazard Risk, HR 1.46, 95% CI
1.05–2.03). The authors suggested that CD subjects and their
physicians should consider pneumococcal vaccination.
Similarly, Ludvigsson et al. [7] evaluated the risk of sepsis in
CD subjects. These authors used the Swedish national health
registers to identify 15,325 subjects with a diagnosis of celiac
disease and 14,494 inpatient reference individuals. The risk of
sepsis was higher than in the control populations, with an HR
of 1.6 (95% CI 1.2–1.9), versus the inpatient reference indivi-
duals, and an HR of 2.6 (95% CI 2.1–3.0), versus the general
population, respectively. A strong association was found with
sepsis due to pneumococcal infection, with an HR of 2.5 (95%
CI 1.2–5.1) versus the inpatient reference individuals, and an
HR of 3.9 (95% CI 2.2–7.0), versus the general population,
respectively. In the same study it was proposed that CD sub-
jects are at risk of sepsis from other bacterial infections than
pneumococcal disease and suggested that other mechanisms
apart from hyposplenism may contribute to increase this risk.
Walters et al [26], in their commentary about data from United
Kingdom and Swedish Celiac Disease registers, found that the
risk of sepsis in these patients was higher than hip fracture
and lymphoma. Peters et al. [27], in a Swedish study on 10,032
Swedish celiac patients hospitalized from January 1964 to
December 1993, reported 818 celiac patient deaths, with
a Standardized Mortality Ratio (SMR) for pneumonia of 2.9.
Grainge et al. [28], in a prospective cohort study, assessed
an approximately 37% higher risk of death in CD patients than
in the general population. The study, performed in southern
Derbyshire (United Kingdom) included 1,092 celiac patients.
A statistically significant increase in all-cause mortality was
observed (SMR 1.37, 95% CI 1.16–1.62), and respiratory disease
played an important role (SMR 1.57, 21 deaths, 11 due to
pneumonia). More than half of the deaths from respiratory
diseases were thus caused by pneumonia, suggesting that
vaccination may be a possible strategy to reduce mortality
resulting from pneumococcal infection.
These conclusions were not confirmed in another study, by
Abdul Sultan et al. [29]; these Authors performed a similar study
on the British population, quantifying the excess cause-specific
mortality between the CD population and the general popula-
tion, with a follow-up of 10 years after CD diagnosis. Their
analysis did not show the excess of mortality risk indicated by
other studies in the literature (as in the case of cancer, cardio-
vascular disease, etc.) and their conclusions were also valid for
respiratory diseases. The authors concluded that the results
should reassure patients and practitioners that there is no risk
of excess cause-specific mortality in CD patients compared to
the general population, except for a slight excess risk of death
from non-Hodgkin’s lymphoma.
More recently, Zingone et al. [30] evaluated the risk of
community-acquired pneumonia in CD patients; they studied
9,803 patients with celiac disease and 101,755 controls and
found 179 and 1,864 community-acquired pneumonia events,
respectively. The absolute rate of pneumonia was similar in
both celiac disease patients and controls: 3.42 and 3.12 per
1,000 person-years, respectively (HR 1.07, 95% CI 0.91–1.24).
However, there was a 28% increased risk of pneumonia in
unvaccinated celiac disease subjects compared to unvacci-
nated controls (HR 1.28, 95% CI 1.02–1.60). On the other
hand, CD patients vaccinated against pneumococcal infection
did not present this risk (HR 0.88, 95% CI 0.70–1.10). The
authors concluded that the unvaccinated subjects were
exposed to a greater risk and that vaccination should be
a safe and effective strategy to limit this risk.
Emilsson et al. [31] assessed whether intestinal mucosal
healing or persistent villous atrophy could influence the risk
of infections in CD patients. The authors found no significant
differences between the two groups regarding any type of
infection, and intestinal mucosal healing did not influence the
risk of serious infections requiring hospital-based medical
treatment. The authors did not evaluate hyposplenism and
suggested that hyposplenism may persist even after intestinal
mucosal healing. This could explain why there is no difference
in the risk of infection between the two groups.
Finally, a recent meta-analysis [10] evaluated the risk of
pneumococcal infection compared to the general population,
showing a higher risk in CD patients than in the general
population (Odds Ratio, OR, 1.66, 95% CI 1.43–1.92).
4. International experience of pneumococcal
vaccination
Data on vaccination in CD patients are only available from
England. A retrospective audit [32] showed that only 19.3% of
celiac patients aged below 65 had received the pneumococcal
vaccine in 2013, and these data were confirmed by Zingone
et al. [30] who reported that only 26.6% of CD patients had
received vaccination after the diagnosis.
Better vaccination rates were demonstrated by Di Sabatino
et al. [33] in a different setting; they registered vaccination cover-
age, mortality and infection rates in all patients who underwent
splenectomy over a 6-year period (2004–2009). In this study,
reasons for splenectomy in the 216 identified patients were, in
order: hematologic disorders, solid tumors, traumatic rupture,
and other causes. Only 67.6% patients received at least one of
the four vaccines (against S. pneumoniae, N. meningitidis,
H. influenzae type B, and influenza). Obviously, this indicated
a poor compliance with recommended vaccination. Overall, the
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mortality rate was significantly greater in unvaccinated than in
vaccinated patients. Of the 21 reported cases of overwhelming
post-splenectomy infection, 8 were fatal and 5 potentially vac-
cine-preventable.
5. Type of vaccine
Many types of vaccines are available on the market and it is
currently unclear which type of vaccination is preferable in CD
patients. Some scientific and health authorities recommend
the use of PCV-10 and PCV-13 (pneumococcal conjugate vac-
cine, valent-10 and −13) in children and adult patients with
alterations of innate and adaptive immunity. Furthermore, the
CRM197 diphtheria protein (i.e. the carrier protein for the
conjugate vaccine) changes the nature of the response from
T-independent to T-dependent, making this vaccine particu-
larly suitable in infants, especially below the age of 2 years,
when the splenic IgM-memory B cell pool is still immature.
Similarly, adult hyposplenic patients, in whom the IgM-
memory B cell pool is depleted, would benefit from PCV-13,
as its T-dependent mechanism bypasses the immunological
impairment due to the lack of IgM-memory B cells [34].
However, this kind of vaccine is recommended by current
guidelines only in infancy. PPV 23 (pneumococcal capsular
polysaccharide vaccine), whose protective action is based on
the production of opsonizing anti-capsular antibodies by
means of a T-independent mechanism, is at present recom-
mended in asplenic/hyposplenic children above 5 years old
and in adults, since it is associated with a poor or absent
response in children under 5 years [35,36].
On the other hand, the current international literature also
suggests using pneumococcal conjugate vaccine instead of the
capsular polysaccharide vaccine in adult patients with hyposplenia
or asplenia due to its T cell-dependent mechanism, which should
be not compromised in these clinical conditions [21]. Therefore, in
naïve patients PCV-13 (1 dose) is recommended, followed by PPV-
23 (1 dose) at least 8 weeks later. In patients who have previously
received PPV-23, PCV-13 is administered ≥1 year later. A booster
dose of PPV-23 after 5 years is also suggested [37].
6. Do we vaccinate all cd patients?
To date, no subgroup of subjects at greater risk of pneumo-
coccal infection has been identified within the group of CD
patients. A limitation bias of previous studies is the lack of
analysis of splenic function and, more generally, of the quan-
tification of the immunological deficit in CD patients, which
can predispose to an increased risk of invasive pneumococcal
disease. However, an analysis of splenic function and size is
not routinely performed in CD patients [11]. It is important to
underline that asplenia is a risk factor strongly associated with
invasive pneumococcal disease, quantified by Backhaus et al.
[38] in a recent study as RR = 14.08 (95% CI 10.38–19.10).
We can suggest two practical approaches to select CD
patients who could benefit from vaccination, thus avoiding the
necessity to vaccinate all newly diagnosed CD patients and
consequently saving money. First, from a simple, clinical point
of view, it is reasonable to vaccinate CD patients with advancing
age at diagnosis, concomitant AID, CD complications (refractory
CD, ulcerative jejuno-ileitis, collagenous sprue), previous history
of major infections/sepsis and/or thromboembolism, and sple-
nic atrophy [11]. Second, the presence of a small-sized spleen
could be investigated by abdominal ultrasound, which can be
included in the routine evaluation of patients with suspected
CD. Evaluating the percentage of pitted erythrocyte levels in
blood films can be a further way to help decide whether or not
to vaccinate patients.
7. Conclusion
At present, there is no study in the literature on CD patients with
hyposplenism that quantifies the risk of invasive pneumococcal
disease, even if the functional impairment of the spleen is a well-
known risk factor for pneumococcal infection [21].
Most authors, in accordance with the British Society of
Gastroenterology guidelines, suggest that pneumococcal vac-
cination in CD patients is a safe and effective method for the
prevention of pneumococcal infections [20]. However, studies
in the literature show conflicting data on the excess risk of
pneumonia, invasive pneumococcal disease, sepsis and mor-
tality in CD patients compared to the general population.
In the 14–65 age group there is in fact an excess of risk, in
part likely due to a lack of pneumococcal vaccination, in the
absence of vaccination schemes [10].
It is necessary to identify those subgroups of CD patients
that could be exposed to a greater risk on the basis of the
course of CD and degree of splenic function deficiency.
A systematic evaluation of spleen function would be useful
in CD to select the patients who may benefit from vaccination,
but it is not currently performed and there are no unanimous
indications about the methods to be used.
At present, in the international literature, there are no studies
to verify whether gluten and active CD can affect the pneumo-
coccal vaccination. Anania et al. [39] showed that immunological
responses to other vaccines in CD children are not different from
those in the general population, except those for hepatitis B.
In conclusion, pneumococcal vaccination should be per-
formed in CD patients, considering the increased risk of invasive
pneumococcal disease in unvaccinated CD patients, as well as
the safety and efficacy profile of the PCV vaccine in asplenic
subjects. However, it does not seem logical, nor economically
viable, to vaccinate all newly diagnosed CD patients. Other
strategies to identify, and thus to protect, CD patients at risk
should be evaluated and applied on a large scale.
8. Expert opinion
What are the key weaknesses in clinical management
so far?
Currently, hyposplenism, a well-known risk factor for pneumo-
coccal infection, is not routinely researched and evaluated in
celiac patients.
What potential does further research hold? What is the
ultimate goal in this field?
A systematic evaluation of spleen function should be useful in
CD to select the patients who may benefit from vaccination, to
reduce the risk of invasive pneumococcal disease.
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What research or knowledge is needed to achieve this
goal and what is the biggest challenge in this goal being
achieved?
Considering that hyposplenism affects more than one-third of
celiac patients, and that it is strongly related to a higher risk of
infections, every physician should investigate for signs of
hyposplenism on peripheral blood smear in CD patients. The
finding of an atrophic spleen on abdominal ultrasound should
then lead the physician to assess spleen function.
Is there any particular area of the research you are finding
of interest at present?
It might be of practical interest to better explore the mechanism
by which malnutrition and increased intestinal permeability may
predispose to an impairment of the immune system’s ability to
respond to infections in celiac patients, and how a gluten-free
diet reverses immunological impairment in celiac patients.
8.1. Five-year view
It is reasonable to speculate that within the next five years
hyposplenism will be routinely researched in celiac patients
and that all celiac patients with impaired immunologic function
will undergo a complete vaccination protocol, including
S. pneumoniae, N. meningitidis, H. influenzae type B, and influenza.
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